Back to results
US 2015/0306198 A1Published application
Aspartate-ß-hydroxylase Induces Epitope-specific T Cell Responses in Tumors
AssigneeRhode Island Hospital
InventorJack R. Wands
Life of this patent
Estimating the term…
Abstract
The present invention provides a peptide-based immunotherapy for ASPH-expressing tumors.
Claims20
A composition comprising a therapeutically effective amount of a purified aspartate-β-hydroxylase (ASPH) peptide, wherein said peptide comprises at least 7 amino acids in length and fewer amino acids than the full length ASPH protein and wherein said peptide comprises an HLA class I or class II-restricted epitope sequence.
Dependencies are inferred from the claim text.